Derek Lowe analyzes GSK’s response and says they have a pretty strong case:
My take on this is that the company has a pretty strong case so far, certainly strong enough to wait for the ongoing trials to settle the issue. What never fails to disappoint me, though, is the way that stories like this are jammed into ready-made templates. Depending on the editorial writer, the appearance of the NEJM paper became “FDA Corrupt, Broken: Snores While Dangerous Drugs Kill Thousands”, or “Giant Drug Company Sells Heart Attack Poison, Doesn’t Give Hoot”. Or maybe just “Drug Approval System Completely Broken – Again”.
Related posts:
- Avandia: Collateral damage
- Avandia: The RECORD study
- Avandia, MI, and cardiac death
- COURAGE trial: The NEJM strikes back
- Does Avandia cause heart attacks, and why the RECORD study is important
- Number needed to treat: Time to let the secret out
- Torcetrapib failed even worse than thought
KevinMD.com on Facebook
Comments on this entry are closed.